60.5% of African American providers advised their African American patients to consume less salt (P<.001). Thirty-one percent of primary health care providers reported the biggest barrier to counseling their prehypertensive and hypertensive patients about sodium intake was that “patients are unlikely to comply”; 22% cited “lack of time”; and 11% reported “patients have other immediate health issues.”

Comment. The majority of primary health care providers agree that their patients should reduce sodium intake; report providing specific advice in line with recommended strategies; and counsel patients with prehypertension, hypertension, or chronic kidney disease to consume less salt. In contrast to 2010 dietary guidelines, a minority of health care providers report counseling patients with diabetes or older patients to consume less salt. Also, a minority of providers of race/ethnicity groups other than African American report counseling African American patients to consume less salt.

The most frequent types of advice provided to patients were in line with current recommended strategies to reduce sodium intake. Interestingly, the majority of health care providers also indicated they advise patients to remove the salt shaker or add less salt during cooking, despite current knowledge that for most people these behaviors are unlikely to result in major salt reduction.

Our results suggest that more effort is required to inform health care providers about the need for all patients to reduce sodium intake and their ability to make a difference in their patient’s behavior. Specifically, the primary care physicians and nurse practitioners who are more concerned about patient care may be more likely to respond and respondents may overstate their counseling behaviors. However, physicians were selected to be representative of the age, sex, and race/ethnicity of the American Medical Association master file.

Jing Fang, MD, MS
Mary E. Cogswell, DrPH, RN
Nora L. Keenan, PhD
Robert K. Merritt, MA

Author Affiliations: Division for Heart Disease and Stroke Prevention, National Center for Chronic Disease Prevention and Health Promotion, Centers for Disease Control and Prevention, Atlanta, Georgia.

Correspondence: Dr Fang, Division for Heart Disease and Stroke Prevention, National Center for Chronic Disease Prevention and Health Promotion, Centers for Disease Control and Prevention, 4770 Buford Hwy NE, Mail Stop K-47, Atlanta, GA 30341-3717 (jiang@cdc.gov).

Author Contributions: Dr Fang had full access to the data and takes responsibility for the integrity of the data and the accuracy of the data analysis. Study concept and design: Fang, Cogswell, and Merritt. Acquisition of data: Fang and Keenan. Analysis and interpretation of data: Fang, Cogswell, and Merritt. Drafting of the manuscript: Fang and Merritt. Critical revision of the manuscript for important intellectual content: Fang, Cogswell, Keenan, and Merritt. Statistical analysis: Fang and Cogswell. Administrative, technical, and material support: Merritt. Study supervision: Keenan and Merritt.

Financial Disclosure: None reported.

Disclaimer: The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention.

Online-Only Material: The eTable is available at http://www.archintermed.com.


The FDA and New Safety Warnings

In response to postmarket drug safety surveillance and research data, the US Food and Drug Administration (FDA) and drug manufacturer may take 1 of 2 types of action. In extreme cases the FDA may remove a drug from the market. More often the product label or package insert is revised to reflect newly discovered risks. The most clinically significant new information is added to 1 of 3 legally defined sections of the prescribing information: (1) a boxed warning (information that is essential to be considered when prescribing the drug); (2) a contraindication (clinical situations when a drug’s risks clearly outweigh its benefits); and (3) a warning (adverse reactions with reasonable evidence of a causal association, reactions that may require discontinuation, or reactions that interfere with a laboratory test).

We analyzed 1 calendar year of these major label changes to provide insights into this safety program. We report the number of actions, severity of events, and nature and scope of the safety information. We also describe the types of drugs affected, whether they were recently approved drugs or established treatments, and what type and level of scientific evidence was used to support these label changes.
Methods. Major safety regulatory actions during 2009 were defined as drug withdrawals for safety, new or revised boxed warnings, contraindications, or warnings for approved prescription drugs. For each action we calculated the years since initial drug approval and identified the brand name or generic status. We categorized the cited evidence source (ie, clinical trial, meta-analysis, epidemiological study, adverse event report). We also evaluated whether the scientific evidence was derived directly from studies of the target drug or inferred from studies of other drugs either with similar chemical structure and mechanism of action or that were indicated for use in the same patient population. A complete description of the study methods is available in the eAppendix (http://www.archinternmed.com).

Results. In 2009, the FDA approved 181 major safety regulatory actions, including 1 drug safety withdrawal, 25 new boxed warnings, 19 new contraindications, 90 new warnings, and 46 revisions of previous actions (Table). Among the newly identified adverse effects were suicidal behavior, life-threatening viral infections, renal failure, and increased cancer risk in children. Adverse event reports from drug manufacturers or through the MedWatch program were the predominant source of scientific information and formed the basis of 77 of 135 new regulatory actions (57%) and 19 of 25 new boxed warnings (76%). Clinical studies were cited as the evidence source for 26 of 135 actions (19%) but only 2 were derived from statistically significant differences and 1 was based on a single study case. A large FDA meta-analysis of suicidal behavior and antiepileptic drugs generated warnings for 19 drugs. In 23 of 135 new actions (17%), the scientific evidence was derived from other drugs, with 15 based on similar chemical structure and mechanism, and 8 based on the same indication and/or patient population. The safety actions occurred a median of 11 years after initial approval and included 61 drugs marketed for 15 years or more; only 36 actions involved drugs within first 5 years after approval.

Comment. These major safety regulatory actions disclose clinically significant risks of widely used drugs, typically many years after approval. Scientific evidence cited to alert physicians about new risks for marketed drugs used notably less rigorous methods than the well-controlled, blinded, and randomized clinical trials used to document benefit prior to approval. When reported adverse events supported the warning, little or no detail was provided about the number and type of reports relied on or any systematic analysis performed.

Some of the most extensive changes involved class warnings applied to a group of drugs without distinguishing between them. All drugs indicated for epilepsy treatment got the same suicidal behavior warning, even those not included in the meta-analysis and drugs with markedly different mechanisms of action. The class warning was extended to 1 benzodiazepine—clonazepam (Klonopin; Hoffmann-La Roche Ltd) with an indication in epilepsy treatment—but not to other benzodiazepines. In another case the FDA announced and put similar suicidal behavior and violence warnings on 2 smoking cessation treatments—varenicline (Chantix; Pfizer Inc) and bupropion hydrochloride (Zyban; GlaxoSmithKline)—even though the FDA’s unpublished but publicly available studies revealed that varenicline accounted for 10 times as many reports as bupropion and had higher risks. The 11-year median time since approval for actions in this 1-year study was markedly higher than the 7 years reported in a 2002 study of boxed warnings or withdrawals since 1975. Improving postmarket drug safety requires timelier ascertainment of drug risks together with higher quality and better documented scientific evidence.

Thomas J. Moore, AB
Sonal Singh, MD, MPH
Curt D. Furberg, MD, PhD

Author Affiliations: Institute for Safe Medication Practices, Alexandria, Virginia (Mr Moore); Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland (Dr Singh); and Division of Public Health Sciences, Wake Forest University School of Medicine, Winston-Salem, North Carolina (Dr Furberg).

Correspondence: Mr Moore, Institute for Safe Medication Practices, 101 N Columbus St, Ste 410, Alexandria, VA 22414 (tmoore@ismp.org).

Author Contributions: Study concept and design: Moore, Singh, and Furberg. Acquisition of data: Moore and Singh. Analysis and interpretation of data: Moore, Singh, and Furberg. Drafting of the manuscript: Moore and Singh. Critical revision of the manuscript for important intellectual content: Moore, Singh, and Furberg. Statistical analysis: Moore and Singh. Study supervision: Furberg.

Financial Disclosure: None reported.

Delirium at the time of discharge is associated with poor outcomes.4 Patients with delirium during hospitalization, and mortality even over a 1-year follow-up period compared with patients without delirium at the time of discharge.1 Patients with delirium during hospitalization had 2.5-times higher average costs per day compared with patients without delirium in a study reviewing 1-year health care costs associated with delirium in the elderly population.1

Given the poor outcomes for untreated delirium and the existence of known interventions, identifying delirium prior to discharge is especially important. The Care Transitions Intervention includes educating patients and their caregivers about red flags—the signs and symptoms that should trigger outreach for follow-up care before patients’ conditions require emergency department visits or hospital readmission—and delirium can be incorporated into this portion of the Care Transitions Intervention. As Alici points out, delirium must first be recognized and documented before any interventions can occur, including hospital-based measures as well as delirium-specific coaching and red flags. A delirium screen such as the Confusion Assessment Method can be performed by less-skilled individuals and could therefore be feasible for hospital staff to incorporate into their standard patient assessments for at-risk patients, such as elderly patients. We believe that the routine adoption of a delirium screening tool, such as the Confusion Assessment Method, would increase the medical recognition and management of delirium during and following patients’ hospitalizations.

Rosa R. Baier, MPH
Rebekah L. Gardner, MD
Rachel Voss, MPH
Kristen Butterfield, MPH
Stefan Gravenstein, MD, MPH

Author Affiliations: Healthcentric Advisors (formerly Quality Partners of Rhode Island) (Mss Baier, Voss, and Butterfield and Drs Gardner and Gravenstein), and De-